Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866846 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| SCHEMBL29715383 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| SCHEMBL32677077 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| SCHEMBL1491696 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| SCHEMBL29707282 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| Hydrochloric Acid SCHEMBL30665771 | 0.98 | KDM4E (0.55) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| Hydrochloric Acid SCHEMBL10749367 | 0.98 | KDM4E (0.55) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| Hydrochloric Acid SCHEMBL8724704 | 0.98 | KDM4E (0.55) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| Hydrochloric Acid SCHEMBL14059291 | 0.98 | KDM4E (0.55) | KDM4EALDH1A1CYP1A2GAACYP2D6 | |
| SCHEMBL27478435 | 0.85 | MEN1 (0.47) | KMT2AMEN1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105294833-B | Isoquinolin -3- formyl-RI-OBzl are prepared, nanostructure, activity and application | 首都医科大学 | 2018-09-07 | — | — | CN | claimed |
| CN-105777712-B | Tetrahydroisoquinoliderivs derivs and its application | 沈阳药科大学 | 2018-05-22 | — | — | CN | claimed |
| CN-104211767-B | The formamido group acyl oligopeptides of isoquinolin 3, it is prepared, nanostructured, antitumor activity and application | 首都医科大学 | 2017-08-18 | — | — | CN | claimed |
| CN-105315333-A | Isoquinoline-3-formyl-RV-OBzl, and preparation, nano structure, activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2016-02-10 | — | — | CN | claimed |
| CN-105315334-A | Isoquinoline-3-formyl-RF-OBzl, and preparation, nano structure, activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2016-02-10 | — | — | CN | claimed |
| CN-105294833-A | Isoquinoline-3-formyl-RI-OBzl, preparation therefor, nanostructure thereof, activity thereof and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2016-02-03 | — | — | CN | claimed |
| CN-105218625-A | Isoquinoline class derivate, its preparation, nanostructure, active and application | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-06 | — | — | CN | claimed |
| CN-105218629-A | Isoquinoline 99.9-3-formyl-RC-OBzl, its preparation, nanostructure, active and application | UNIV CAPITAL MEDICAL SCIENCES | 2016-01-06 | — | — | CN | claimed |
| CN-104211767-A | Isoquinoline-3-formylaminoacyl oligopeptides, preparation, nano structure, antitumor activity, and applications thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-12-17 | — | — | CN | claimed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4276533-A1 | CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276534-A1 | MASK BLANK, RESIST PATTERN FORMING PROCESS AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION | Shin-Etsu Chemical Co., Ltd. (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-4585758-A | Angiotensin-converting enzyme inhibitors | USV PHARMACEUTICAL CORP. (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0155809-A2 | Renin inhibitors containing statine or derivatives thereof | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0127090-A2 | Angiotensin-converting enzyme inhibitors | USV PHARMACEUTICAL CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0018549-B1 | TETRAHYDROISOQUINOLINE COMPOUNDS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Tanabe Seiyaku Co., Ltd. (JP) | 1981-12-30 | — | — | EP | disclosed |
| US-4294832-A | HYPOTENSIVE AGENTS, ANGIOTENSIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1981-10-13 | — | — | US | disclosed |
| EP-0018549-A2 | Tetrahydroisoquinoline compounds, process for preparing them and pharmaceutical compositions containing them | Tanabe Seiyaku Co., Ltd. (JP) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | KDM4E 2035/4885ALDH1A1 2432/4885CYP1A2 1701/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | KDM4E 732/4885ALDH1A1 2021/4885CYP1A2 3724/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | KDM4E 732/4885ALDH1A1 2021/4885CYP1A2 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.